Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, spending approximately HKD 9.0082 million to repurchase 1.6008 million shares on February 6, 2026 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech (02158) and raises its target price to HKD 11, indicating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product layout to secure a core position in the wave of healthcare AI infrastructure development [1] - The company has embedded itself in national AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates strong technical capabilities, ranking alongside top products in accuracy and traceability, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's substantial accumulation in medical data governance and knowledge construction, attributing unique advantages to the quality and authority of its data sourced from top hospitals [2] - The company's To-G business segment shows more predictable profitability compared to consumer applications, benefiting directly from increased hospital AI budgets and national project tenders [2] - Financial forecasts have been adjusted, with expectations for the big data platform revenue to grow by 17% and 30% year-on-year in fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]

Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech and raises its target price to HKD 11, anticipating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product portfolio to secure a core position in the wave of healthcare AI infrastructure development [1] - The company has embedded itself in national AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions and alleviating the burden on healthcare personnel through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates solid technical capabilities, ranking alongside top products in accuracy and traceability, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's strong foundation in medical data governance and knowledge construction, attributing its unique advantage to the large scale and quality of data sourced from top hospitals [2] - The company's To-G business segment shows more predictable profitability compared to consumer applications, benefiting directly from increased hospital AI budgets and national project tenders [2] - Citigroup has adjusted its financial forecasts for Yidu Tech, projecting a 17% and 30% year-on-year growth in big data platform revenue for fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]

Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, signaling strong market confidence and positive business fundamentals [1] Group 1: Share Repurchase Activity - On February 5, Yidu Tech announced a share repurchase, buying approximately 1.88 million shares at around HKD 5.55 per share, totaling over HKD 10 million [1] - This marks the ninth consecutive trading day of intensive repurchases, with a cumulative expenditure of approximately HKD 44 million [1] - The daily repurchase amount continues to maintain a high level, indicating strong commitment from the company [1] Group 2: Southbound Capital Inflow - Southbound capital has shown consistent interest in Yidu Tech, with net purchases for nine consecutive days, totaling HKD 44.97 million as of February 2 [1] - As of February 2, southbound investors held approximately 237 million shares, representing 22.14% of the company's total shares, with a market value of about HKD 1.333 billion [1] - The combination of the company's share repurchase and the inflow of southbound capital sends a positive signal to the market [1] Group 3: Business Fundamentals - The positive movement in capital aligns with the company's recent business developments, including partnerships for "AI + health management" in Shenzhen and the launch of a general medicine AI assistant with Chongqing Medical University [1] - The ongoing share repurchases and capital inflows reflect market recognition of the company's business value and strategic execution capabilities [1]

Group 1 - The core viewpoint of the article is that Yidu Technology has been actively repurchasing its shares, signaling confidence in its business value and strategic execution [2] - On February 5, Yidu Technology announced a share buyback of approximately 1.88 million shares at a price of about 5.55 HKD per share, totaling over 10 million HKD [2] - This marks the company's ninth consecutive trading day of share repurchases, with a cumulative expenditure of around 44 million HKD [2] Group 2 - According to Wind data as of February 2, southbound funds have net bought Yidu Technology shares for nine consecutive trading days [2] - The company's ongoing buybacks, along with the continuous inflow of southbound funds, convey a positive signal to the market [2] - Yidu Technology has recently partnered with Shenzhen Nanshan Hospital for an "AI + Health Management" initiative and launched a general medicine diagnostic AI assistant in collaboration with Chongqing Medical University First Affiliated Hospital [2]

Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, signaling strong market confidence and positive business fundamentals [1] Group 1: Share Repurchase Activity - On February 5, Yidu Tech announced a share repurchase, buying approximately 1.88 million shares at around HKD 5.55 per share, totaling over HKD 10 million [1] - This marks the ninth consecutive trading day of intensive repurchases, with a cumulative expenditure of approximately HKD 44 million [1] - The daily repurchase amount continues to maintain a high level, reflecting the company's commitment to enhancing shareholder value [1] Group 2: Capital Inflows - Southbound funds have shown consistent interest in Yidu Tech, with net purchases for nine consecutive days, totaling HKD 44.97 million as of February 2 [1] - As of February 2, southbound funds held approximately 237 million shares of the company, representing 22.14% of total shares, with a market value of about HKD 1.333 billion [1] - The combination of the company's share repurchase and the inflow of southbound funds sends a positive signal to the market [1] Group 3: Business Fundamentals - The positive capital movements align with the company's recent business developments, including partnerships for "AI + health management" with Shenzhen Nanshan Hospital and the launch of a general medicine AI assistant with Chongqing Medical University First Affiliated Hospital [1] - The ongoing share repurchase and capital inflow reflect market recognition of the company's business value and strategic execution capabilities [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 醫渡科技有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF30 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股 ...

Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, demonstrating strong confidence in its intrinsic value and long-term growth potential [1][3]. Group 1: Share Buyback Details - On February 4, Yidu Tech repurchased 1.92 million shares at approximately HKD 5.6 per share, with a total expenditure exceeding HKD 10 million, marking the eighth consecutive trading day of intensive buybacks [1]. - The cumulative buyback amount has surpassed HKD 33 million, indicating a significant commitment to enhancing shareholder value [1]. - On February 3, Yidu Tech ranked among the top three companies in Hong Kong for share buybacks, with a buyback scale of 1.4628 million shares and HKD 8.2179 million [2][3]. Group 2: Market Response and Investor Sentiment - The company's ongoing buyback efforts, combined with sustained interest from southbound funds, reflect a strong market confidence in Yidu Tech's value [3]. - As of January 30, southbound funds have net purchased Yidu Tech shares for eight consecutive days, totaling HKD 41.7065 million, further indicating positive investor sentiment [3].